Status:
RECRUITING
Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy
Lead Sponsor:
Istituto Ortopedico Rizzoli
Collaborating Sponsors:
Università Degli Studi del Sannio Dipartimento di Ingegneria Benevento
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola
Conditions:
Bone and Soft Tissue Tumors
Eligibility:
All Genders
2-85 years
Brief Summary
DEEPLY aims to improve sarcoma therapy by the development of an innovative nanophotonic delivery approach to be applied in the future as an integrated local therapy for patients with inoperable tumors...
Eligibility Criteria
Inclusion
- Patients eligible for the study will be male or female, with an age ranging from 0- to 85 years, undergoing surgery or biopsy for STSs or BSs including osteosarcomas.
- Included patients may have undergone or may be still in treatment with chemotherapy (also neo-adjuvant settings), targeted therapy, radiotherapy, or combination therapy.
- IRST will enroll only adult patients (age \> 18 years).
- Signed informed consent from all subjects enrolled in the study. IOR patients will have to sign both the specific project Informed Consent and the IOR Biobank Informed consent.
Exclusion
- Patients not affected by STSs or BSs will be excluded from the study, as well as patients with multiple primary tumors.
Key Trial Info
Start Date :
August 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06599957
Start Date
August 30 2024
End Date
August 30 2026
Last Update
September 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Ortopedico Rizzoli-OSOTT
Bologna, Emilia-Romagna, Italy, 40136
2
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola, Emilia-Romagna, Italy, 47014